The decrease of LINE-1 methylation levels in MS patients without clinical activity could be related to an increased expression profile of genes associated with IFNβ response, such as those involved in the upregulation of production of antiinflammatory mediators such as TGF-β1, IL1ra, IL6 and IL1046–48. Here, IFNB1 is linked to myeloid sarcoma.